Ikena Oncology, Inc. (IKNA)

Market Cap	62.25M
Revenue (ttm)	9.16M
Net Income (ttm)	-68.17M
Shares Out	48.26M
EPS (ttm)	-1.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,600
Open	1.390
Previous Close	1.350
Day's Range	1.270 - 1.390
52-Week Range	1.020 - 7.640
Beta	0.33
Analysts	Strong Buy
Price Target	10.67 (+727.13%)
Earnings Date	May 13, 2024

About IKNA

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: IKNA

Financial Performance

In 2023, Ikena Oncology's revenue was $9.16 million, a decrease of -41.35% compared to the previous year's $15.62 million. Losses were -$68.17 million, -0.87% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $10.67, which is an increase of 727.13% from the latest price.

Price Target

$10.67

(727.13% upside)

Analyst Consensus: Strong Buy